Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UNITEDHEALTH GROUP INC director Frederick William McNabb III reported an automatic share-based compensation event. He acquired 64 shares of common stock on March 17, 2026 with a reported price of $0.0000 per share, described as dividend equivalents on vested deferred stock units. These dividend equivalents are immediately vested and follow the same terms as the underlying deferred stock units. After this credit, his directly held common stock position increased to 14,774 shares, reflecting a small, routine adjustment rather than an open-market purchase.
UnitedHealth Group director Timothy Patrick Flynn reported a small stock award tied to existing deferred compensation. On March 17, 2026, he acquired 79 shares of UnitedHealth common stock at $0.0000 per share as dividend equivalents on vested deferred stock units, which are immediately vested and follow the same terms as the underlying units. Following this grant, his direct holdings total 10,239 shares of common stock, and he also holds 6,033 shares indirectly through a trust.
HEMSLEY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director and CEO Stephen J. Hemsley received an award of 61 shares of common stock on March 17, 2026. This was reported as a grant or award of dividend equivalents on vested deferred stock units at a stated price of $0.0000 per share, and the dividend equivalents are immediately vested and follow the same terms as the underlying deferred stock units.
After this transaction, Hemsley directly holds 362,628.942 shares of common stock. He also has indirect holdings of 355.091 shares through a 401(k) plan and 692,255 shares held by trusts, which include 10,380 shares previously held directly and contributed to the trusts on January 29, 2026 in a transaction noted as exempt from reporting pursuant to Rule 16a-13.
UNITEDHEALTH GROUP INC director Charles D. Baker reported a small share award. On March 17, 2026, he acquired 14 shares of Common Stock at a price of $0.00 per share as a grant/award acquisition.
According to the footnote, these shares represent dividend equivalents paid on vested deferred stock units, which are immediately vested and subject to the same terms as the underlying deferred stock units. After this transaction, Baker directly holds 1,820 shares of UnitedHealth Group common stock.
UNITEDHEALTH GROUP INC executive Erin McSweeney, EVP & Chief People Officer, reported an acquisition of company common stock through a share-based award. She received 64.885 shares as dividend equivalents on outstanding restricted stock units at a stated price of $0.00 per share.
These dividend equivalents are subject to the same vesting terms as the underlying restricted stock units and will be forfeited if those units do not vest. Following this award, McSweeney directly holds a reported total of 15,552.923 UnitedHealth Group common shares.
UNITEDHEALTH GROUP INC director Michele J. Hooper received 292 shares of common stock as dividend equivalents on vested deferred stock units. These dividend equivalents are immediately vested and follow the same terms as the underlying deferred stock units, meaning they function as routine, compensation-related accruals rather than an open-market purchase. After this acquisition, Hooper directly holds a total of 41,586 shares of UnitedHealth Group common stock, indicating this is a small, incremental increase to an existing position.
UNITEDHEALTH GROUP INC director Kristen Gil reported a small stock award. On March 17, 2026, Gil acquired 8 shares of common stock at $0.00 per share, described as dividend equivalents paid on vested deferred stock units and subject to the same terms as those units. After this award, Gil holds 2,083 shares directly and 3,800 shares indirectly through a trust, indicating this is a routine, compensation-related update rather than an open-market trade.
UNITEDHEALTH GROUP INC director Scott Gottlieb reported a small compensation-related equity acquisition. He received 1 share-equivalent of common stock on 2026-03-17 as dividend equivalents paid on vested deferred stock units, which are immediately vested and follow the same terms as the underlying units. After this award, he directly owns 126 shares of common stock.
Conway Patrick Hugh reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC reported that Patrick Hugh Conway, Chief Executive Officer of Optum, received a grant of 125.021 shares of common stock on March 17, 2026 at a price of $0.00 per share. These shares represent dividend equivalents on his outstanding restricted stock units and will vest or be forfeited under the same conditions as those units. Following this award, his directly held common stock position increased to 18,604.991 shares, indicating a routine, compensation-related adjustment rather than an open-market purchase.
UNITEDHEALTH GROUP INC Chief Accounting Officer Dennis Andrew Stankiewicz filed an initial ownership report showing direct holdings of common stock and several grants of non-qualified stock options. He holds 10,137.881 shares of common stock and multiple option awards with exercise prices between $252.37 and $521.97 expiring from 2030 through 2036, many vesting in annual installments.